贝斯美（300796.SZ）10月15日在投资者互动平台表示，公司碳五延伸产品中，环戊烷系列项目已实现 平稳生产并批量销售。正戊烯作为戊酮装置联产品，产能为4,000吨/年，相关产品正常生产销售。公 司"年产20,000吨特种醇系列绿色新材料项目"已进入建设阶段，按计划有序推进。二甲戊灵原药方面， 公司通过全资子公司宁波捷力克开展全球化销售，2024年产品覆盖79个国家和地区。 每经AI快讯，有投资者在投资者互动平台提问：想了解下公司碳五延伸环戊烷及环戊烯，正戊烯等碳 五产品目前销售情况如何，环戊烷有没有出口或者大型冰箱工厂供货或者意向供货情况？还有特种醇， 及4硝基苯建设情况如何？二甲戊灵原药还有和巴斯夫供货吗？ （文章来源：每日经济新闻） ...

8月19日，贝斯美（300796）（300796）发布2025年半年度报告，上半年公司实现营收7.76亿元，同比 增长16.57%；归母净利润3470.64万元，同比增长109.70%；扣非净利润3287.01万元，同比增长 125.95%；基本每股收益0.1元/股，同比增长100.00%。 随着环保农药产业政策持续释放红利，叠加公司在技术研发、品牌积淀等多维度构筑的强劲市场竞争 力，共同构成了贝斯美自产农药业务持续稳健增长的核心动能；子公司捷力克凭借在全球农药流通领域 积累的丰富专业经验、成熟营销网络，以及数量众多的海外农药登记证等先发优势，有力助推公司农药 出海业务拓展，形成了自产与出口协同并进的良好发展格局。同时，公司依托戊酮装置及间戊二烯原材 料预处理技术切入碳五新材料领域，把握高端产品进口替代机遇，构筑差异化壁垒。多板块协同发力， 为贝斯美持续拓展市场空间、实现高质量发展奠定坚实基础。 强链补链筑基，以绿色发展引领农药行业未来 随着农业现代化进程加速与绿色发展理念深化，高效、安全、经济、环境友好的农药新产品推广，已成 为推动农业可持续发展的关键抓手。中研普华产业研究院《"十四五"农药行业发展形势研究 ...

Group 1: Company Overview and Strategic Projects - Shaoxing Bestmay Chemical Co., Ltd. is actively expanding its product lines in the C5 chemical sector, including the "Annual Production of 8,500 Tons of Ketone Series Green New Materials Project" and the "Annual Production of 12,100 Tons of Cyclopentane Series Green New Materials Project" [1][2][3] - The company has achieved stable operation of its ketone facility, with product quality meeting standards and sales status being steady [2][3] - The company is positioned as a leader in the domestic C5 comprehensive utilization field, enhancing its product offerings and reducing reliance on imports [2][3] Group 2: Financial Performance and Growth - In 2024, the company reported a revenue of 1.328 billion RMB, representing a year-on-year growth of 89.97% due to the full-year consolidation of Ningbo Jielike's operations following an 80% stake acquisition [5][6] - The revenue from C5 series products increased from 11.67 million RMB in 2023 to 73.12 million RMB in 2024, marking a growth of 5.26 times [20] Group 3: Research and Development - The company invested 45.52 million RMB in R&D in 2024, a 13.7% increase from the previous year, and holds 58 authorized patents, including 32 invention patents [6][8] - The focus on R&D has led to the development of proprietary technologies that enhance production efficiency and reduce costs, such as low-temperature continuous nitration and solid salt recovery technologies [18] Group 4: Market Position and Competitive Advantage - The company is recognized as a national high-tech enterprise and has established a complete production and R&D capability for the herbicide Dimethenamid-P, covering the entire industry chain from intermediates to formulations [8][15] - The company has a strong export presence, with its subsidiary Jielike operating in 79 countries, achieving over 75% of its revenue from overseas markets in 2024 [15][19] Group 5: Future Outlook and Strategic Initiatives - The company plans to continue focusing on environmentally friendly pesticide development and expand its C5 new materials product line to enhance market share and profitability [5][15] - The company aims to leverage its existing market channels and the acquisition of Jielike to penetrate emerging markets in South America, Africa, and Southeast Asia, thereby increasing sales of Dimethenamid-P [11][15]